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Abstract
Background: The aim of the study was to determine the relationship between the presence of p.G60 = polymorphism
(c.180C > T; rs497078) CTRC and the incidence together with the clinical course of acute pancreatitis (AP).
Methods: Two hundred ninety-nine people suffering from AP and 417 healthy volunteers were subjected to the study.
DNA was isolated from blood samples.
Results: CTRC p.G60 = polymorphism (c.180C > T) occurred more frequently in the AP group (p = 0.015). The CT and TT
genotype was found in 27.8% of the AP patients and in 19.9% of the healthy subjects (p = 0.017). No significant
correlation was found between having the CT and TT genotype and the severity of the AP clinical course. In 6
patients (2%) with the CT genotype, a SPINK1 gene mutation was found, while in the control group it was found
in 3 patients (0.7%), (p > 0.05). All patients with the present SPINK1 mutation with the CT genotype had a moderate or a
severe course of the disease (p = 0.0007).
Conclusions: CTRC polymorphism Hetero p.G60=; c.180C > T increases the risk of an AP occurrence and together with
the SPINK 1 mutation, may be responsible for a more severe course of the disease.
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Background
In recent years, a higher incidence of acute pancreatitis
(AP) has been reported in many countries. Poland is one
of the countries with a high incidence rate, which equals
79,7/100000 [1].
It is generally accepted that the direct cause of the
disease is the activation of digestive enzymes in the acinar
cells. An inflammatory condition in the pancreatic area
initiates a cascade of immunological events, which play a
significant role in disease development [2]. The course of
the disease is usually mild, but in about 20% of patients,
moderate or severe AP develops [1]. The most common
causes of AP include cholelithiasis and alcohol consump-
tion, however some studies point to the importance of
genetic mutations and polymorphisms [3–6]. Such an
approach indicates a complex and multifactorial nature of
acute pancreatitis. Genetic factors should be taken into
account together with other factors which cause the
disease [7]. So far, there is no long term follow-up that
would allow us to understand the role of genetic factors
during the first onset of AP [8].
Some mutations play an important role in the develop-
ment of pancreatitis. In normal conditions (genes are
not mutated), trypsin in the pancreatic parenchyma is
not activated, whereas mutations of genes cause disor-
ders in secretion, enzymes are activated and the muta-
tions predispose the pancreas to pancreatitis. These
factors include: the gene coding cationic trypsinogen
(PRSSI) and serine peptidase inhibitor Kazal type 1
(SPINK1). Other genes regulating trypsin, such as the
independent calcium-sensing receptor gene (CASR), the
gammaglutamyltransferase1 gene (GGT1), the cystic
fibrosis transmembrane conductance regulator (CFTR)
and the recently discovered chymotrypsin C gene
(CTRC), seem to be the disease modifiers with a lower
risk. The protein CTRC codes chymotrypsin C, which is
produced by the pacreatic acinar cells [7].
Several papers have been published by Sahin-Toth’s
group elucidating the complex regulatory function of
CTRC on trypsinogen activation. Namely, trypsinogen
activation in active trypsin is controlled by two processes.
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Firstly, the cleavage of the trypsinogen activation peptide
accelerates the autoactivation of trypsinogen. The second
mechanism is based on the cleavage of the peptide in the
trypsinogen calcium binding loop which promotes its
degradation [9–13].
Based on the GTex site (http://www.gtexportal.org/
home/), data concerning the rs497078 SNP QTL, the TT
genotype correlated with a lower expression of the
CTRC gene in comparison to the CT and CC genotype
in normal pancreas. However, it should be mentioned
that these results are based on 149 cases with the fol-
lowing genotype distributions CC: 113, CT:33, TT:3.
Bearing the above in mind, and taking into consideration
the complex nature of, the regulation of trypsinogen
activation by CTRC, it is possible that the T allel could
be a risk factor for pancreatitis. However, in order to
reveal the true function of the T allel, more studies are
needed [14].
The aim of the study was to determine the relationship
between the presence of the p.G60 = polymorphism
(c.180C > T; rs497078, NM_007272.2:c.180C > T), CTRC
and the incidence and clinical course of acute pancrea-
titis in the Polish cohort.
Methods
The study included 299 patients with acute pancreatitis,
being inhabitants of the Kielce Region in Poland who
gave their informed consent for the collection of genetic
material. The control group consisted of 417 healthy
inhabitants who accepted the invitation to take part in
the research.
The diagnosis of mild, moderate or severe acute pan-
creatitis (SAP), according to the Atlanta 2012 classifica-
tion, was the criterion for inclusion in the study. A
diagnosis of AP was based on the joint interpretation of
medical history, a physical examination and targeted
laboratory tests. The diagnosis was based upon the satis-
faction of at least 2 of the following 3 criteria: (1) upper
abdominal pain of sudden onset, frequently radiating
towards the back; (2) lipase or amylase activity in
serum > 3 times the upper limit of normal; and (3)
results of imaging tests that allow one to obtain cross-
sectional images: computed tomography (CT), nuclear
magnetic resonance (NMR), or ultrasonography (USG).
In the analysis of the etiology of AP, taking a person’s
medical history can determine the following: alcohol
consumption, the occurrence of concomitant diseases,
drug intake, procedures undergone and endoscopic
retrograde cholangiopancreatography (ERCP). Biliary
etiology was confirmed based on USG, CT, NMR, and/or
ERCP, only if there were indications for the performance
of these procedures, for example, icterus. Endoscopic
ultrasonography was performed in some patients to
confirm biliary AP. Alcohol consumption was evaluated
with the Short Alcohol Dependence Data (SADD)
Questionnaire, and self-estimated alcohol consumption
via an interview. Acute pancreatitis was diagnosed if a
patient gained ≥10 points on the SADD Questionnaire,
or if the period of alcohol abuse lasted ≥1 year, and the
daily dose was 40 g of pure ethanol.
Exclusion criteria were a diagnosis (which took place
during interviews) of chronic pancreatitis, as well as the
enlargement of the Wirsung duct and calcifications larger
than 5 mm, which were diagnosed during transabdominal
ultrasonography.
The control group included adult volunteers selected
by random sampling, without any apparent concomitant
diseases that could have affected the structure and
expression of genes to be tested in the study.
The study was approved by the Committee on Bioethics
at the Faculty of Medicine and Health Sciences, Jan
Kochanowski University in Kielce. Each patient and
member of the control group gave their informed con-
sent to genetic testing.
Study samples
Whole blood samples were submitted to the Department
of Molecular Diagnostics (Holycross Cancer Center,
Kielce, Poland) for genetic testing.
DNA Extraction
Whole blood extraction was performed using the Genomic
Blood AX Micro Gravity (A & A Biotechnology, Gdańsk,
Poland) purification system, which uses gravity technology.
The DNA was extracted manually with a volume of
0.1 ml of blood, then the DNA concentration was mea-
sured using the Nano Drop (Thermo Scientific, Waltham,
MA, USA).
HRM
This PCR (forward 5'-CTGACACACAGCCCTCCC −3
'and reverse 5'-ATGGCCAGGTCTCAGGGTAT -3') for
the amplification of the target sequence (162 bp) in the
CTRC gene were designed using Primer3 web software
(RefSeq NM_007272.2).
Similarly, the following primers were (F-TTGCTAT-
GAACTCAAGAATGGAGA;
R-CCGATTTTCAAAACATAACACTG) projected for
the amplification of SPINK1.
HRM reactions were performed using reagents from
the Qiagen and the Qiagen Rotor Gene machine.
The reactions were carried out using a 15ul volume
according to the following mixture: polymerase -5ul
(Cat. No. 206546), water -7ul, primer F-1ul (final con-
centration 0,67uM), primer R -1ul (final concentration
0,67uM), DNA - 1ul (20–50 ng) /per sample.
Amplifications were performed using a 5-min initial
denaturation at 95 °C followed by 37 cycles of 10 s at
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95 °C, 30 s at 65 °C, with an initial 10 cycles of touch-
down (10/cycle) and 10 s at 72 °C.
Then the melting step was carried out in the range of
800 to 930 for CTRC, and 75–80 °C for exon 3 SPINK1.
The HRM of studied samples was done in parallel with
control WT. Then, all the studied samples were analyzed
relative to the control curve (WT).
Genotypes were assigned based on shape differences
between curves. The samples with the greatest vertical
distance from the WT melting curves were heterozy-
gotes, and melting curves between the heterozygous and
WT samples were homozygotes (Fig. 1).
We have comprehensively validated our HRM
methodology. 20% (143 samples) of all the studied
samples have been sequenced. The concordance with
genotypes assigned based on melting method was
100%. Finally, our results are supported by a similar
frequency of mutation detected in a healthy popula-
tion in comparison to data from the 1000Genome
project.
Sequencing
The curves diverging in shape from the control curve
(WT) were verified by applying capillary sequencing.
The concentration of DNA in these samples was mea-
sured using the electrophoresis device Multina (Shi-
madzu, Japan). For the Sanger sequencing reaction, PCR
amplification products were purified using 10 U (Cat.
No. EN 0582) of exonuclease I and 1 U of phosphatase
Fast-AP (Cat. No. EF 0651) (Thermo Fisher). The reac-
tion was incubated for 15 min at 37 °C, followed by
20 min at 80 °C.
Sequencing reactions were performed using forward
and reverse sequence-specific primers (described above)
and the ABI-PRISM Big Dye Terminator version 3.1 kit
(Applied Biosystems, Foster, CA; Cat. No. 4337450),
according to the manufacturer’s instruction manual.
Sequencing reactions were analyzed using the 3130
Capillary Sequencer (Applied Biosystems, Foster, CA).
The generated sequences were compared relative to
the reference sequence RefSeq (NM_007272.2), using
the NCBI Blast Nucleotide program.
Statistical methods
Categorical data were expressed as number and per-
centage distributions. Proportions were compared
between groups by the chi-square test or the Fisher’s
exact test as appropriate. Odds ratios (OR) with 95%
confidence intervals (95% CI) were calculated using the
univariate logistic regression model. Quantitative data
were characterized by medians, and the non-parametric
Mann–Whitney U test was used for comparisons
between groups. The two tailed p-value <0.05 was con-
sidered to be statistically significant.
All computations were performed using the statistical
package R, version 3.1.2 (R Core Team (2014). R: A lan-
guage and environment for statistical computing. R
Foundation for Statistical Computing, Vienna, Austria.
Fig. 1 Example of HRM analysis. Green curve – CC genotype (c.180C), orange – CT genotype (c.180C > T), light orange – TT genotype (c.180 T)
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URL http://www.R-project.org/.) and StatSoft, Inc.
(2014). STATISTICA (data analysis software system),
version 12. www.statsoft.com.
Results
The study group included 299 patients who had acute
pancreatitis (127 female, 172 male); the median age
being 56 years (62 in women, 53 in men). The course of
AP was mild in 69.6% of patients, moderately severe in
13.4%, and severe in 17.0%. The dominant etiological
factors of the disease was cholelithiasis (41.8%) and alco-
hol (30.8%), but in 25.4% of the patients no other cause
than an idiopathic cause of incidence was identified.
The control group consisted of 417 healthy inhabitants
of the Kielce Region (271 women and 146 men), with
the median age being 46 (46 in women, 48 in men, in a
general good state of health).
Both in the test group, as well as in the control group,
no differences in the age distribution was observed
between the patients with the CT and TT, versus the CC
genotype. In the test group, the median of the patients’
age with the CC genotype was 57 years, and with the
CT and TT genotype, 53 years (p = 0.22). In the control
group, the median age of the patients with the CC geno-
type was 47 years, and with the CT and TT genotype,
45 years (p = 0.68).
The CT and TT genotype was found in 27.8% of
the AP patients and in 19.9% of the healthy subjects
(p = 0.017). The frequency of the TT genotype occur-
rence was not statistically different between the groups of
healthy and sick individuals (p = 0.803). However, the CT
genotype was significantly more frequent in the AP group
compared with the control group (p = 0.015) (Table 1).
To reinforce our analysis, we performed a comparison
of allelic distribution between our control group and
other European populations (Utah residents with Northern
and Western European ancestry, Finnish, British, Iberian,
Toscani) using data from the 1000 Genomes project [15].
We found that the allelic distribution in our control
group is similar to the Toscani and Finish populations
(T:10%, C:90%) (p = 0.518), but is different when we
take into account the Utah, British and Iberian popula-
tions (T:8%, C:92%). The genotype distribution was in
agreement with the Hardy –Weinberg equilibrium for
cases (p = 0.50) and controls (p = 0.52). The T allele was
the minor allele, and was observed more frequently in
cases than controls (14.7% vs. 10.7%, p = 0.023).
In order to analyze allelic distribution in the studied
population, we applied a few genetic models (Table 2.)
With the four models, after applying the Bonferroni
corrections to the results of the p-value, less than 0.05/
4 = 0.0125 are found to be statistically significant. It
should, however, be kept in mind that this amendment
is very conservative, so one can assume that the results
of the p-value = 0.014 are on the border of statistical
significance. We found that after applying the Bonferroni
correction, only the genotypic and dominant model are on
the border of statistical significance.
The presence of the CT and TT genotype was not sta-
tistically significantly dependent on gender, neither in
the test group (women: 38/127 (29.9%) vs. men: 45/172
[26.2%], p = 0.56, test chi2), nor in the control group
(women: 53/271 [19.6%] vs. men: 30/146 [20.5%], p = 0.91,
test chi2). The patients’ age average with the CT and TT
genotype was similar, both in the test group (45.2 vs. 45.5)
as well as in the control group (54.1 vs. 55.3).
Only in one case of an AP patient with the CT geno-
type (p.G60=; c.180C > T), was the occurrence of pan-
creatic disease mentioned in the family history (AP).
No significant dependency was found between having
the CT and TT genotype and the severity of the AP
clinical course, but in patients with the TT genotype
(p.G60=; c.180 T), no severe AP was observed, which is
contrary to the patients with the CT genotype (25% of
whom experienced a moderate course of the disease and
27.5% a severe course of the disease; p > 0.05) (Table 3).
The confirmed cause of the incidences was not related
to the CT and TT genotypes, except for the cases in
which a carcinoma was diagnosed in the AP course. In
this group of sick subjects, 50% of the cases concerned
Table 1 The comparison of the frequency of the occurrence of the CTRC genotype (p.G60=; c.180C, c.180 T, c.180C > T) in the AP
patients’ group and the control group of healthy individuals





N = 299 N = 417
Female Male Totals Female Male Totals
CTRC Polymorphism
Homo p.G60=; c.180 T
1 (0.8%) 4 (2.3%) 5 (1.7%) 4 (1.5%) 2 (1.4%) 6 (1.4%) 0.042 0.803 1.2 0.4-3.9
CTRC Polymorphism
Hetero p.G60=; c.180C > T
37 (29.1%) 41 (23.8%) 78 (26.1%) 49 (18.1%) 28 (19.2%) 77 (18.5%) 0.015 1.6 1.1-2.2
CTRC Polymorphism
Homo p.G60=; c.180C
89 (70.1%) 127 (73.8%) 216 (72.2%) 218 (80.4%) 116 (79.5%) 334 (80.1%) 0.014 0.6 0.5-0.9
*p value for the difference in genotype distribution among AP patients and control group of healthy individuals
**to compare Totals
AP acute pancreatitis, CTRC chymotrypsinogen C, OR odds ratio
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patients with the CT genotype (p.G60=; c.180C > T).
Homo (p.G60=; c.180 T) CTRC polymorphism was
found only in 3.3% of patients with alcohol etiology
(Table 3). Alcohol was also a frequent cause of AP
relapses in patients with the TT genotype: 2/3 of the
cases (66.7%) vs. 50.6% patients with the CC and 38.7%
with the CT genotype.
Recurrent AP (RAP) was more frequent in patients
with the CT and TT genotype compared with the
group without relapses, differently from the CC geno-
type patients, but statistical significance was not con-
firmed (p = 0.47) (Table 3).
The relationship between the polymorphism of CTRC
Hetero p.G60=; c.180 C > T (CT), known as the AP
genetic risk factors, the SPINK 1 (p.N34S) gene muta-
tions was analyzed. In six patient (2%) with the CT
genotype, a SPINK1gene mutation was found (p.N34S),
while in the control group it was found in 3 patients
(0.7%), (p > 0.05). All patients with the present SPINK1
(p.N34S) mutation with the CT genotype had a moderate
or a severe course of the disease (p = 0.0007) (Table 4).
A moderate or severe course of the disease was
observed in 6/6 of the patients with the SPINK1
(p.N34S) mutation and the CTRC CT genotype vs. 8/15
of the patients with the SPINK1 (p.N34S) mutation and
the CC genotype (p = 0.06 in the Fisher’s exact test). The
observed correlation at the edge of statistical significance
suggests that increasing the size of the group may con-
firm a more severe course of the disease in the case of
the combination of the SPINK 1 mutation and the CTRC
CT genotype.
The SPINK 1 mutation and CTRC polymorphism
Hetero p.G60=; c.180C > T were equally frequent
among the patients with disease relapses and without
(2/111 vs. 4/188, p = 1 in the Fisher’s exact test).
Discussion
In recent years, molecular studies have allowed us to
identify mutations of key genes, including the CTRC
gene, which might be crucial in the development of pan-
creatitis [16].
So far, only a few papers have been published that con-
firm the relationship of the CTRC gene polymorphism
and an increased tendency to chronic pancreatitis, how-
ever, there is a lack of research in which patients with
acute pancreatitis have taken part. Pathogenic CTRC
variants were found both in the patients with CP and in
the control group involving healthy individuals, thus,
they should be considered risk factors, however, four
CTRC variants have been recognized as pathogenic:
p.A73T, p.V235I, p.R254W and p.K247_R254del [17].
Many authors observed a significant association of the
synonymous variant c.180C > T (p.G60=) with CP [7, 16,
18, 19]. In the Indian studies, the variant c.180C > T
(p.G60=) was found in 23–29% of the subject popula-
tion. It increased the incidence risk by about 2.5 times in
heterozygotes and tenfold in homozygotes [19]. In our
paper, the analysis of the frequency distribution of the
CTRC gene genotypes revealed a statistically significant
correlation between the frequency of the CT (c.180C > T,
Table 2 Genetic models and allelic distribution in pancreatitis
population
Genetic model Comparison OR 95% CI p-value
Allelic T vs. C 1.44 1.04-2.01 0.023
Genotypic CT vs. CC 1.57 1.10-2.24 0.014
TT vs. CC 1.29 0.39-4.27 0.68
Dominant CT/TT vs. CC 1.55 1.09-2.19 0.014
Recessive TT vs. CT/CC 1.17 0.35-3.85 0.80
Table 3 The frequency of the occurrence of the CTRC gene polymorphisms (p.G60=; c.180C > T) in the acute pancreatitis patients
depending on the severity of the clinical course, etiology and disease relapses
Analysis p.G60 =





CT No. 78 CC No. 216 TT vs. CC CT vs. CC TT/CT vs. CC
P value P value P value
Severity of the course
Mild AP 208 5 (2.4%) 54 (26%) 149 (71.6%) 0.801 0.979 0.908
Moderate AP 40 - 10 (25%) 30 (75%)
Severe AP 51 - 14 (27.5%) 37 (72.5%)
Etiology of AP
Alcohol 92 3 (3.3%) 21(22.8%) 68 (73.9% 0.418 0.521 0.661
Gallstones 125 2 (1.6%) 33 (26.4%) 90 (72%)
Idiopathic 76 21 (27.6%) 55 (72.4%)
Cancer 6 3 (50%) 3 (50%)
Reccurrences of AP
Yes 111 3 (2.7%) 31 (27.9%) 77 (69.4%) 0.355 0.584 0.473
AP acute pancreatitis, CTRC chymotrypsinogen C
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p.G0=) genotype occurrence and developing acute pan-
creatitis (p < 0.05) with the adjusted odds ratio 1.6 (95% CI
1.1–2.2). What’s more, applying the four genetic models
(Table 2), we have found that none of them have statistical
significance. However, genotyping (TT vs. CC) and the
dominant model (CT/TT vs. CC) are on the border of
statistical significance.
Acute pancreatitis, especially recurring and chronic
pancreatitis, should be treated as a complex disorder, in
which various genetic and environmental factors can be
of significance, which, when they co-occur, are responsible
for increasing the risk of the disease development, a
change in its character or a growing intensity of the
developing process [20]. Tremblay et al. [21] conducted
research in a group of 38 patients with acute pancreatitis
and severe abdominal pain, as well as hypertriglyceridemia
(Lipoprotein Lipase Deficiency- LPLD) and 100 healthy
individuals (control). As a result of sequencing the CTRC
and SPINK1 genes, they found a positive correlation
between the frequency of rehospitalization and a com-
bination of the gene variants: rs545634 (IVS) (CTRC) –
rs11319 (UTR-3’) (SPINK1) [OR = 41.4 (CI:2.0–848.0);
p = 0.016]. LaRusch et al. [5] analyzed the influence of the
variants CTRC p.G60 (c.180 T) on the risk of developing
CP and RAP in a group of patients of European origin.
Alcohol and tobacco smoking usually co-occurred, but
the frequency of CTRC c.180 T in CP, but not in RAP,
was higher among non-drinking smokers (10,8%),
which suggests that smoking, not alcohol, may play a
more significant role in this dependency. A frequent
variant CTRC c.180 T may have an influence on the
modifications of progression from RAP to CP, especially
in patients with the CFTR or SPINK1 mutations, who
drink alcohol or smoke tobacco [5].
The studies on NAPS2 = CV showed that in the group
of 521 patients with CP, there were 25,7% of patients
who had never had AP. A higher percentage of patients
with RAP never consumed alcohol or smoked cigarettes
compared to the CP and control groups [5]. In our
study, alcohol was the dominant cause of developing the
disease in patients with polymorphism Homo c.180 T
CTRC (60%). Alcohol was also a frequent cause of the AP
relapses in patients with the c.180 T genotype (66,7%).
LaRusch et al. [5] found that CTRC c.180C > T alleles
significantly increase the CP risk, but not RAP, which
corresponds to the results of our study, in which no
correlation was found between the disease relapses with
CTRC c.180C > T and polymorphism Homo (c.180 T;
p.G60=). In our study we did not confirm the relation-
ship between CTRC c.180C > T and the SPINK 1, CTRC
polymorphisms and the frequency of AP development,
recurrence and an identified cause of the disease. LaRusch
et al. [5] and Masson et al. [22] reported such a
dependency in reference to the patients with CP. How-
ever, a new finding was the fact that the mutation
SPINK1 (hetero p.N34S), in combination with CTRC
c.180C > T, can be responsible for a more severe course
of acute pancreatitis. Due to the small number of patients
(6 people), one cannot formulate a decisive conclusion
and thus further research is necessary in order to confirm
this dependency.
There is a growing number of studies which reveal
that genetic factors together with environmental factors
may increase the risk of developing pancreatitis.
Conclusions
CTRC polymorphism Hetero p.G60=; c.180C > T
increases the risk of developing acute pancreatitis, and
in combination with the SPINK1 mutation, can be re-
sponsible for a more severe course of the disease.
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Table 4 The description of the AP patients with the confirmed SPINK 1 (p.N34S) mutation and CTRC polymorphism hetero p.G60=;
c.180C > T (CT)
Severity of the course Reccurrences of AP Etiology of AP Pancreatic diseases in family
Mild AP Moderate AP Severe AP Yes No Alcohol Gallstones Idiopathic Cancer Yes No
Patient No. SPINK 1 mutation and CTRC Polymorphism Hetero p.G60=; c.180C > T (CT) n = 6/299 (2%)
1 X X X X
2 X X X X
3 X X X X
4 - X X X X
5 X X X X
6 X X X X
AP acute pancreatitis, CTRC chymotrypsinogen C, SPINK 1 pancreatic secretory trypsin inhibitor gene
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